<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>28</volume><submitter>Bi G</submitter><pubmed_abstract>Lung adenocarcinoma (LUAD) is one of the most common malignancies worldwide. Combination chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the predominant therapeutic regimen; however, chemoresistance greatly limits its curative potential. Here, through CRISPR-Cas9 screening, we identified miR-6077 as a key driver of CDDP/PEM resistance in LUAD. Functional experiments verified that ectopic overexpression of miR-6077 desensitized LUAD cells to CDDP/PEM in both cell lines and patient-derived xenograft models. Through RNA sequencing in cells and single-cell sequencing of samples from patients with CDDP/PEM treatments, we observed CDDP/PEM-induced upregulation of CDKN1A and KEAP1, which in turn activated cell-cycle arrest and ferroptosis, respectively, thus leading to cell death</pubmed_abstract><journal>Molecular therapy. Nucleic acids</journal><pagination>366-386</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9035384</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways.</pubmed_title><pmcid>PMC9035384</pmcid><pubmed_authors>Tan L</pubmed_authors><pubmed_authors>Zheng Y</pubmed_authors><pubmed_authors>Jin X</pubmed_authors><pubmed_authors>Zhan C</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Bi G</pubmed_authors><pubmed_authors>Zhao M</pubmed_authors><pubmed_authors>Huang Y</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Liang J</pubmed_authors><pubmed_authors>Bian Y</pubmed_authors><pubmed_authors>Lu T</pubmed_authors><pubmed_authors>Besskaya V</pubmed_authors></additional><is_claimable>false</is_claimable><name>miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways.</name><description>Lung adenocarcinoma (LUAD) is one of the most common malignancies worldwide. Combination chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the predominant therapeutic regimen; however, chemoresistance greatly limits its curative potential. Here, through CRISPR-Cas9 screening, we identified miR-6077 as a key driver of CDDP/PEM resistance in LUAD. Functional experiments verified that ectopic overexpression of miR-6077 desensitized LUAD cells to CDDP/PEM in both cell lines and patient-derived xenograft models. Through RNA sequencing in cells and single-cell sequencing of samples from patients with CDDP/PEM treatments, we observed CDDP/PEM-induced upregulation of CDKN1A and KEAP1, which in turn activated cell-cycle arrest and ferroptosis, respectively, thus leading to cell death</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-05T00:27:36.872Z</modification><creation>2025-02-19T03:27:48.493Z</creation></dates><accession>S-EPMC9035384</accession><cross_references><pubmed>35505963</pubmed><doi>10.1016/j.omtn.2022.03.020</doi></cross_references></HashMap>